A Phase 2, randomized, placebo-controlled, double-blind clinical study to evaluate efficacy and safety of LAD328 in adult subjects with moderate to severe hidradenitis suppurativa

Status

Not yet recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2025-521865-29-00

Enrollment

3999996

Registered

2026-04-01

Start date

Unknown

Completion date

Unknown

Last updated

2026-04-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

moderate-to-severe hidradenitis suppurativa

Brief summary

Proportion of participants achieving IHS4-55 at XXXX., Safety: Frequency and severity of TEAEs, SAEs, AESIs and AEs leading to discontinuation., Safety: Vital signs, ECG and clinical laboratory parameters.

Interventions

DRUGSODIUM CHLORIDE

Sponsors

Almirall S.A.

Lead SponsorINDUSTRY

Eligibility

Sex/Gender

All

Age

18 Years to 64 Years

Design outcomes

Primary

Measure	Time frame
Proportion of participants achieving IHS4-55 at XXXX., Safety: Frequency and severity of TEAEs, SAEs, AESIs and AEs leading to discontinuation., Safety: Vital signs, ECG and clinical laboratory parameters.	—

Outcome results

None listed

Source: EU CTIS · Data processed: Apr 3, 2026